Print this page    •   Back to Web version of article

Medical News
Gilead's $12,000-a-Year HIV Prevention Pill Fails to Win Physician Support

March 3, 2011

In Boston at this week's 18th Conference on Retroviruses and Opportunistic Infections (CROI), numerous presentations addressed issues surrounding the use of Gilead Science Inc.'s Truvada as an HIV preventative. In late November, researchers reported the results of a study, conducted among healthy men who have sex with men, which showed that taking the AIDS drug reduced the risk of HIV infection by 73 percent among the most adherent participants and by 44 percent overall. The MSM also were provided condoms and counseling.

So far, however, doctors have been reluctant to prescribe Truvada, which costs $12,000 a year and carries a risk of side effects, to their healthy patients.

"We're not seeing people beating down the doors," said Kenneth Mayer, medical research director and co-chair of Boston's Fenway Institute, whose clients include thousands of MSM. Mayer said he knows of no clinic doctor who has prescribed Truvada, which combines emtricitabine and tenofovir, to prevent HIV infection.

Martin Markowitz, clinical director of New York's Aaron Diamond AIDS Research Center, praised the study but added that "it raises more question than it answers. People who can't use a condom, are they likely to take a pill every day? And in the real world, who will pay?"

Presentations at CROI also are exploring other preventive measures, like male circumcision and microbicides, that may be used concurrently with Truvada in some populations, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. "It's almost certainly going to be a combination of things that together will have a major impact," he said.

CDC is convening expert panels to discuss how best to introduce Truvada as an HIV preventative. Demonstration projects that would offer the drug to high-risk, uninfected men are under consideration by the National Institutes of Health and the Department of Health and Human Services. Gilead has announced plans to file for US approval of Truvada as an HIV preventative in the first half of this year.

Back to other news for March 2011

Excerpted from:
Bloomberg News
02.28.2011; Michelle Fay Cortez, Simeon Bennett




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art60744.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.